Clinical Trials
65
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1949
Active, not recruiting
1
1.5%
Completed
28
43.1%
Not yet recruiting
1
1.5%
Recruiting
12
18.5%
Unknown
23
35.4%
No approval data available
- Researchers from the Chinese Academy of Sciences and Qi Biodesign developed programmable synthetic immune receptors that can be introduced into plants to detect pathogen proteins and trigger immune responses. - The platform enables plants to recognize proteins made by specific bacteria, viruses, and fungi, neutralizing threats to essential crops. - The work, published in the peer-reviewed journal Science, establishes a versatile platform for efficient plant immunity engineering. - The technology addresses the rapid breakdown of natural resistance genes by fast-evolving pathogens in large-scale monoculture systems.
- New research in mice overturns the long-held belief that collateral arteries arise from pre-existing arteries, showing instead that capillaries are the primary building blocks of new coronary collaterals. - A CUHK–CAS joint team used a novel genetic lineage-tracing "cell-contact history recorder" to track endothelial cell origins during collateral artery formation after coronary blockage. - The study identifies a VEGFA–YY1 signaling axis as the master driver of capillary-to-artery conversion, with transient mRNA-based VEGFA delivery improving heart function in injured mice. - The findings, published in Science, point to a tractable therapeutic target for ischaemic heart disease, the leading cause of death worldwide.
- Cai Lei, former JD.com VP diagnosed with ALS in 2019, has entered the terminal stage and now communicates solely via eye-tracking technology and AI-recreated voice. - He helped establish China's first ALS pathological sample bank and built the world's largest ALS patient research data platform, connecting tens of thousands of patients. - Nearly 300 drug research pipelines have been advanced, with more than 30 projects entering clinical trials, and some targeted therapies showing potential to slow or halt disease progression. - Cai has personally invested and raised over 100 million yuan ($14.7 million) for ALS research, working 12-hour days despite complete paralysis.
- Chinese researchers have developed a novel mitochondrial capsule transplantation therapy that achieves 80% delivery efficiency compared to less than 5% for naked mitochondria, using red blood cell membrane vesicles as protective capsules. - The therapy successfully restored motor function to near-normal levels in Parkinson's disease mouse models and significantly extended lifespan in mice with mitochondrial genetic diseases. - In patient cells with mitochondrial DNA mutations, the transplanted healthy mitochondria actively integrated with existing cellular networks and compensated for genetic defects by reducing the proportion of malfunctioning mitochondria. - This breakthrough represents the first safe and efficient method for transplanting healthy mitochondria into cells and tissues, offering new therapeutic possibilities for over 1 in 5,000 people worldwide affected by mitochondrial genetic diseases.
- Chinese Academy of Sciences researchers developed a breakthrough method to generate up to 14 million induced NK cells or 7.6 million CAR-iNK cells from a single cord blood stem cell, representing a massive scaling advance for cancer immunotherapy manufacturing. - The innovative three-stage process engineers CD34+ hematopoietic stem cells before maturation, reducing viral vector requirements by up to 600,000-fold compared to traditional mature NK cell modification approaches. - Laboratory testing demonstrated that the engineered CAR-iNK cells effectively reduced tumor growth and extended survival in mouse models of B-cell acute lymphoblastic leukemia, with one-fifth of a cord blood unit potentially yielding thousands of treatment doses.
- Monash University researchers have uncovered the genetic code governing how mutations affect RNA splicing, a critical cellular process for protein production. - The breakthrough enables development of personalized mRNA therapeutics for rare and population-specific diseases previously difficult to treat. - Scientists used the SpliSER tool to analyze millions of splice-sites across 25+ species, revealing patterns that link genetic mutations to disease mechanisms. - The discovery provides a "clear explorable pathway to a cure" for debilitating genetic conditions, with immediate applications expected in therapeutic development.
- Chinese researchers led by Han Shuo at the Chinese Academy of Sciences have developed an engineered nanozyme that functions as a "nano-tagging robot" to precisely identify cancer cells for immunotherapy. - The nanozyme responds to deep-red light or ultrasound and can carry antibodies or ligands to enrich on cancer cell surfaces, clearly tagging them as targets for immune system attack. - The technology achieved good therapeutic effects in experimental mouse tumor models and in vitro clinical tumor samples, with potential to activate whole-body immune memory like a "tumor vaccine." - The breakthrough study was published in Nature and is expected to pave the way for smarter, more efficient next-generation immunotherapies.
- Researchers from the Chinese Academy of Sciences developed SeNExo, a novel therapeutic agent combining neural stem cell-derived exosomes with ultrasmall nano-selenium particles for treating traumatic brain and spinal cord injuries. - The therapy effectively crosses the blood-brain barrier via APOE-LRP-1 interaction and addresses both oxidative damage through ROS scavenging and neuronal repair through exosome-mediated mechanisms. - In mouse models, SeNExo reduced cerebral lesions, improved spatial learning and memory functions in TBI, and promoted locomotor recovery in spinal cord injury cases. - The treatment demonstrates significant potential by downregulating oxidative stress and apoptosis genes while promoting glial homeostasis and enhancing neuron-glia communication networks.
- Chinese researchers successfully developed the first technique to efficiently differentiate human pluripotent stem cells into A10 subtype dopamine neurons, marking a breakthrough in cell therapy for psychiatric disorders. - When transplanted into depression-model mice, the engineered A10 neurons integrated into host neural circuits and significantly reduced anxiety and depression-like behaviors while restoring pleasure-seeking ability. - The study demonstrates proof-of-concept for targeted neural circuit reconstruction as a potential alternative to traditional antidepressants, which affect approximately one-third of treatment-resistant depression patients poorly.
- A comprehensive bibliometric analysis of 4,108 publications reveals hydrogels as a rapidly growing field in cancer drug delivery, with annual publications exceeding 613 in 2024. - Injectable hydrogels offer minimally invasive chemotherapy delivery that reduces systemic side effects while improving therapeutic efficacy through localized drug release and enhanced tumor penetration. - Emerging research trends focus on immunotherapy applications, immunogenic cell death mechanisms, and multifunctional antimicrobial hydrogels that combine cancer treatment with infection prevention. - Current hotspots include carboxymethyl cellulose-based systems, chitosan nanocomposites, and stimulus-responsive hydrogels that enable precise spatiotemporal drug release control.
